HALIFAX, July 20 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF), a developer of rapid diagnostic technology and solutions, announced today the appointment of Daniel Frid as Chief Financial Officer and Sing Chan as Chief Operating Officer.
Mr. Frid is a CFA charterholder and a Certified Management Accountant, with over 15 years of experience in financial management. Most recently, he was a member of the Senior Management Team for Keane Canada Inc., serving as the Director of Finance and Information Technology.
"On behalf of the Board of Directors and the entire MedMira team I am pleased to welcome Dan to MedMira. He will be a valuable member of our executive team, integrating his strategic acumen and operational capabilities as a proven catalyst for innovation, business growth and accountability," said Dr. Jim Smith, Chairman, MedMira Inc. "Our leadership is further strengthened by the appointment of Sing Chan as Chief Operating Officer. Sing has made a significant contribution to the growth and development of MedMira's manufacturing operations and in his new role will bring broader operational leadership to the entire company."
Mr. Chan joined MedMira in 2000 and has held the position of Vice President, Operations since 2004. In this role, Mr. Chan lead the manufacturing, production and information technology departments and was directly involved in improving manufacturing and production efficiencies and the company's overall operation process. Mr. Chan graduated from Acadia University with a Bachelor of Computer Science.
MedMira is a leading developer and manufacturer of flow-through rapid diagnostics. The company's tests provide hospitals, labs, clinics and individuals with reliable, rapid diagnosis for diseases such as HIV and hepatitis C in just three minutes. The company's tests are sold under the Reveal(R), Multiplo(TM) and Miriad brands in global markets. MedMira's rapid HIV test is the only one in the world to achieve regulatory approvals in Canada, the United States, China and the European Union. MedMira's corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada. For more information visit MedMira's website at www.medmira.com.
This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
SOURCE MedMira Inc.
For further information: For further information: Andrea Young, Corporate Communications, MedMira, Tel: 902-450-1588, Email: firstname.lastname@example.org